Joseph C. Scodari will retire from Acurx Pharmaceuticals, Inc.’s Board effective November 13, 2026, then continue as a corporate advisor. His departure stems from no disagreement over operations, policies or practices.
ACXP · Acurx Pharmaceuticals, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These matters raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Nov 12, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $1.03
- Open
- $1.03
- Day range
- $1.03–1.11
- 52-week closing range
- $0.94–6.63
- Average volume, 30 days
- 105K
- Short interest
- 98K · 1.6% of shares · 1.6 days
- Short volume, last session
- 30%
- Last earnings
- Nov 12, 2026
- Latest filing
- 10-Q · Nov 12
- Price history
- Jun 2021 to Nov 2026
Up next
Latest documents
Acurx Pharmaceuticals began enrolling patients on September 29th in the 20-patient Pathfinder trial for multiply-recurrent CDI. Cash totaled $9.7 million at September 30, 2026, and net loss was $2.6 million, or 49 cents per diluted share, for the three months ended September 30, 2026.
Acurx Pharmaceuticals says its ibezapolstat recurrent-CDI pilot enrolled its first patient in the third quarter, ahead of schedule, with up to 20 patients planned. It reported a $6.5 million nine-month net loss and $9.7 million cash as of September 30, 2026.
The board adopted an amendment to the bylaws effective October 29, 2026, reducing the stockholder meeting quorum to one-third of the voting power outstanding and entitled to vote, from a majority previously.
Acurx Pharmaceuticals' 2026 Annual Meeting elected David Luci and Dr. Jack Dean as Class II Directors and ratified CohnResnick LLP as independent auditor for fiscal year ending December 31, 2026, with approximately 52.8 percent quorum present.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ACXP
this stock
Acurx Pharmaceuticals, Inc.
|
$6.24M | -58.6% | — | — | 1.6% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 13, 2026
- This year
- 17
Joseph C. Scodari will retire from Acurx Pharmaceuticals, Inc.’s Board effective November 13, 2026, then continue as a corporate advisor. His departure stems from no disagreement over operations, policies or practices.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ACXP | +4.6% | -9.7% | -46.6% | -1.0% | -58.6% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +10.0% | -3.4% | -41.0% | +4.3% | -63.6% |